Intravitreal Injectable Market

SKU: DMMD1074 | Last Updated On: Sep 24 2022 | Available Formats

>Intravitreal Injectable Market Expected to reach a high CAGR of 5.8% By 2029

Intravitreal Injectable Market is segmented By Drug Class (Anti-VEGF, Steroids, Antibiotics, Antifungals, Antivirals), By Indication (Diabetic Retinopathy, Macular Degeneration, Endophthalmitis, Retinal Vein Occlusions,  Others)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

[150 Pages Report] Intravitreal Injectable Market is expected grow at a high CAGR of 5.8% during the forecast period (2022-2029).

Intravitreal Injectable Market - Strategic Insights

Metrics

Details

Market CAGR

5.8%

Segments Covered

By Drug Class, By Indication, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Intravitreal injection is an effective mode of treatment used to treat retinal diseases, such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. An intravitreal injection is used to place medication directly in the space back of the eye called the vitreous cavity, which is filled with a fluid called the vitreous humor gel. Growing retinal disorders are expected to drive the global intravitreal injectable market over the forecast period at a high pace.

Market Dynamics

Chronic retinal patients often require repeated dosages of intravitreal (IVT) injectable. Thus, growing chronic retinal diseases is the major factor boosting the global intravitreal injectable market. According to WHO (World Health Organization), 2018, around 188.5 million people have a mild vision impairment, and 217 million have moderate to severe vision impairment. Additionally, key manufacturers are focusing on the development of new drugs to meet the needs of patients. For instance, in April 2017, Roche’s ‘Lucentis’ (ranibizumab injection) for diabetic retinopathy was approved by the FDA.

Segment Analysis

Based on drug class, the global intravitreal injectable market is broadly segmented as anti-VEGF, antibiotics, antifungals, steroids. Among all these anti-VEGF accounted for major market share in 2018, and is projected to grow at a high CAGR over the forecast period. Rising prevalence of these chronic retinal diseases has led to the growth of anti-VEGF drugs. Anti-VEGF drugs have proven to be safe for intraocular use as they reduce leakage of fluid in case of eye disorders. Its superior features, such as excellent biocompatibility and impressive pharmacodynamics properties, have led to its increased popularity among ophthalmologists worldwide. Anti-VEGF drugs mostly target chronic retinal diseases, such as diabetic retinopathy, macular degeneration, retinal vein occlusion, and others. According to the American Academy of Ophthalmology, around 2.1 million Americans aged 50 and above have age-related macular degeneration; diabetic retinopathy affects nearly 7.7 million Americans age 40 and older. Thus, growing chronic retinal diseases are expected to drive the anti-VEGF segment in the global intravitreal injectable market.

Geographical Analysis

The global Intravitreal Injectables market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America accounted for a major market share in 2018 and is projected to grow at a significant rate over the forecast period (2019-2026). It is due to the increase in the prescription of retinal biologics. Also, advanced high healthcare facilities, coupled with the growing prevalence of eye disorders. According to CDC (Centers for Disease Control and Prevention), in 2015, an average of 1.8 million Americans aged 40 years and older are affected by macular degeneration, and it is expected to reach 2.95 million by 2020.

Competitive Analysis

Significant players of the global Intravitreal Injectables market are F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Alcon Pharmaceuticals, Valeant Pharmaceuticals International, Inc., Novartis AG, Allergan, Alimera Sciences, ThromboGenics, Inc., Bristol-Myers Squibb Company, and others. Majority of these prominent players are adopting a few organic and inorganic strategies such as product launches, collaboration, and product agreements, and other key developments to enhance their product portfolio in the intravitreal injectables market. For instance, in July 2018, Roche announced the first successful phase II study of a long-acting delivery device for the treatment of neovascular (“wet”) age-related macular degeneration (nAMD).

In August 2018, Regeneron Pharmaceuticals, Inc. announced that its EYLEA® (aflibercept) Injection was approved by the U.S. Food and Drug Administration (FDA).

Trending Topics

Nephrology and Urology Devices Market

Orthokeratology Lenses Market

Compression Therapy Market

FAQ

What is the Intravitreal Injectable Market growth?

The market is growing at a CAGR of 5.8%

What is Intravitreal Injectable Market size in 2021

The Intravitreal Injectable Market size was valued at USD YY million in 2021

Who are the key players in Intravitreal Injectable Market?

F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals, Inc., Alcon Pharmaceuticals, Valeant Pharmaceuticals International, Inc

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest